Healthcare Disparity Efforts: Some Doubts, Stronger Incentives Needed | Managed Healthcare Executive® State of the Industry Survey
Survey shows some support but also some doubt about how effective the efforts will be. A sizable minority (43%) of respondents indicated that they believe stronger incentives are needed.
The combination of the uneven effects of COVID-19 pandemic and the killing of George Floyd put a spotlight on healthcare disparities in 2020. Almost every organization in U.S. healthcare rushed to address the issue in some way.
Responses to the Managed Healthcare Executive® annual State of the Survey showed support for the efforts. Only a small minority (13%) of the 450 respondents indicated that they agreed with the statement that the “underlying causes are too fundamental for healthcare to take on” and more than one-third (36%) agreed that addressing healthcare disparities is a good investment in dealing with the causes of health and illness.
However, the survey also revealed some doubts and belief that changes are needed. Nearlyhalf (47%) of the respondents indicated that they agree that efforts to address healthcare disparities are “well intentioned but unlikely to have a substantial effect.”A slightly smaller proportion (43%) said that financial incentives need to be strong to make them effective.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More
